🔗 Share this article

Elected officials have expressed alarm that the United Kingdom's series of deals with Washington are "lacking a solid foundation." This stems from revelations that a recently announced deal on pharmaceutical tariffs, which commits to zero tariffs in exchange for the NHS facing higher prices, lacks any formal legal text beyond limited headline terms contained within government press releases.

An Agreement in Principle Only

The US-UK pharmaceuticals agreement, hailed as a "landmark" achievement, exists as an "statement of intent" without formal ratification. Critics have noted that the public statements from the UK and US governments frame the deal in markedly contrasting terms. The British version focuses on securing "duty-free access" as a singular success, while the American announcement dwells on the commitment for the NHS to pay 25% more for new medications.

"We face a genuine possibility that the UK government has agreed to terms to raise drug prices in return for little more than a assurance from President Trump," commented David Henig, a trade policy analyst. "History shows he has form for not keeping promises."

Wider Concerns Amidst a Suspended Agreement

Anxieties have been heightened by Washington's move to pause the £31bn "tech prosperity deal", which was previously heralded as "a transformative pact" in the bilateral relationship. The US pointed to a insufficient movement from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions agreed to for British farmers as part of an initial accord have not been formally approved by the US, despite a looming January deadline. "Our understanding is that the US has not finalized the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have admitted unease that the government's agreements with the US are flimsy and unreliable. One minister was quoted as stating the series of agreements as "built on sand," while another described the situation as the "new normal" in the transatlantic relationship, marked by "additional layers of volatility and unpredictability."

Layla Moran, chair of the health select committee, stated: "What is even more astonishing than Trump's temper tantrums is the UK government's optimistic assumption that his administration is a trustworthy negotiator. The NHS is too precious to be gambled with."

Government Downplays Risks, Points to Gains

Officials have downplayed the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been pushing for the agreement, seeking certainty on imports and pricing, making it less abstract than the paused tech deal.

Officials concede that instability is inherent in dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a concrete advantage," one official said.

Nevertheless, delays have arisen in carrying out the broader trade deal. Promised access for British beef have yet to be finalized, and the assurance to "eliminate duties on UK metals" has remains unmet, with tariffs remaining at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "constructive" meetings between UK and US officials in Washington.